5-HT1A Agonists Counteract VMAT Inhibitor Side-Effects

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

VMAT inhibitors like tetrabenazine used to treat movement disorders induce significant side-effects such as depression and Parkinsonism, limiting their clinical utility due to the risk of depression, suicidality, and drug-induced Parkinsonism.

Innovation Solution

Administering selective serotonin 5-HT 1A receptor agonists, such as befiradol, to patients treated with VMAT inhibitors to minimize side-effects of depression and Parkinsonism by interacting with the 5-HT 1A receptors and reducing depressive-like symptoms and catalepsy behavior.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If VMAT inhibitors like tetrabenazine are administered to treat movement disorders, then the motor symptoms are improved, but depression and Parkinsonism side-effects occur

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoiddepression and Parkinsonism side-effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent introduces 5-HT1A receptor agonists as an intermediary substance that mediates between the VMAT inhibitor treatment and the patient's neurological system. This agonist acts as a protective intermediary that counteracts the harmful effects of VMAT inhibitors on serotonin neurotransmission, thereby preventing depression and Parkinsonism while allowing the VMAT inhibitor to continue treating movement disorders

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent converts the harmful depletion of serotonin caused by VMAT inhibitors into a beneficial therapeutic opportunity by administering 5-HT1A receptor agonists. These agonists specifically target the serotonin system to compensate for the inhibitor's effects, transforming the side-effect mechanism into a dual-therapy approach where the harm (serotonin depletion) is directly addressed by a targeted intervention that benefits the patient

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

2Object-affected harmful factors

If VMAT inhibitors are used to control chorea and involuntary movements, then movement symptoms are reduced, but the risk of suicidality and severe depression increases

Engineering Contradiction:

Improveinvoluntary movementsVSAvoidsuicidality and depression risk

Core Design Contradiction:

Object-affected harmful factorsVSObject-generated harmful factors

Solution Approach 1:

The patent applies preliminary anti-action by administering 5-HT1A receptor agonists either concurrently with or in anticipation of VMAT inhibitor treatment. This pre-emptive approach establishes protective serotoninergic tone before the VMAT inhibitor can deplete serotonin stores, thereby preventing the development of depressive symptoms and suicidality risk rather than treating them after they occur

Inventive Principle:

Principle #9Preliminary anti-action

3Productivity

If higher doses of VMAT inhibitors are administered to improve symptom control, then movement disorder symptoms are better managed, but side-effects are intensified

Engineering Contradiction:

Improvesymptom control efficacyVSAvoidside-effect severity

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the therapeutic parameter by introducing a second agent (5-HT1A agonist) with different pharmacological properties that counterbalance the dose-dependent side effects of VMAT inhibitors. This allows the VMAT inhibitor to be administered at higher effective doses for better symptom control, while the agonist compensates for the increased serotonin depletion, effectively decoupling the relationship between dose and side-effect severity

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The use of 5-HT 1A receptor agonists effectively reduces depression and Parkinsonian symptoms induced by VMAT inhibitors, thereby improving the therapeutic efficacy and tolerability of treatments for movement disorders like Huntington's disease, L-DOPA-induced dyskinesias, Tourette's syndrome, and tardive dyskinesia.

Implementation Method 1

administering selective serotonin 5-HT 1A receptor agonists, such as befiradol, to patients treated with VMAT inhibitors to minimize side-effects of depression and Parkinsonism by interacting with the 5-HT 1A receptors and reducing depressive-like symptoms and catalepsy behavior

Methodology Applied

Scientific EffectReceptor agonism:

Data Source

PatentEP3664787B1Use of selective serotonin 5-HT1a receptor agonists for treating side-effects of VMAT inhibitors

Publication Date: 2022.07.20 NEUROLIXIS

Figure 1~2
Figure 3
Figure 4

AI summary

The present invention relates to the reduction of the side-effects induced by tetrabenazine or other inhibitors of vesicular monoamine transporter (VMAT), in the treatment of central nervous system disorders such as Huntington's disease, L-DOPA-induced dyskinesias in Parkinson's disease, Tourette's syndrome or tardive dyskinesia. The invention comprises administering to a patient in need thereof an effective amount of activates selective serotonin 5-HT1A receptors agonist, whereby the side-effects of depression or Parkinsonism induced by tetrabenazine or other VMAT inhibitors are minimized.